165 related articles for article (PubMed ID: 35163707)
1. miR-196a Upregulation Contributes to Gefitinib Resistance through Inhibiting GLTP Expression.
Liu BJ; Li FF; Xie YX; Fan CY; Liu WJ; Qiu JG; Jiang BH
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163707
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
3. miR-145-5p Modulates Gefitinib Resistance by Targeting NRAS and MEST in Non-Small Cell Lung Cancer.
Yu C; Li B; Wang J; Zhang Z; Li S; Lei S; Wang Q
Ann Clin Lab Sci; 2021 Sep; 51(5):625-637. PubMed ID: 34686504
[TBL] [Abstract][Full Text] [Related]
4. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
Li Q; Wang Y; He J
J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
[TBL] [Abstract][Full Text] [Related]
5. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT.
Jiao D; Chen J; Li Y; Tang X; Wang J; Xu W; Song J; Li Y; Tao H; Chen Q
J Cell Mol Med; 2018 Jul; 22(7):3526-3536. PubMed ID: 29664235
[TBL] [Abstract][Full Text] [Related]
6. Exosomes-transmitted miR-7 reverses gefitinib resistance by targeting YAP in non-small-cell lung cancer.
Chen R; Qian Z; Xu X; Zhang C; Niu Y; Wang Z; Sun J; Zhang X; Yu Y
Pharmacol Res; 2021 Mar; 165():105442. PubMed ID: 33497805
[TBL] [Abstract][Full Text] [Related]
7. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
Ge P; Cao L; Chen X; Jing R; Yue W
BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
[TBL] [Abstract][Full Text] [Related]
8. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
[TBL] [Abstract][Full Text] [Related]
9. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
[TBL] [Abstract][Full Text] [Related]
10. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
[TBL] [Abstract][Full Text] [Related]
11. Cryptotanshinone strengthens the effect of gefitinib against non-small cell lung cancer through inhibiting transketolase.
Cao L; Hong W; Cai P; Xu C; Bai X; Zhao Z; Huang M; Jin J
Eur J Pharmacol; 2021 Jan; 890():173647. PubMed ID: 33049304
[TBL] [Abstract][Full Text] [Related]
12. miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met.
Cao X; Lai S; Hu F; Li G; Wang G; Luo X; Fu X; Hu J
Sci Rep; 2017 Jun; 7(1):2939. PubMed ID: 28592790
[TBL] [Abstract][Full Text] [Related]
13. miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37.
Kim MS; Kim SH; Yang SH; Kim MS
Cancer Res Treat; 2022 Apr; 54(2):445-457. PubMed ID: 34352998
[TBL] [Abstract][Full Text] [Related]
14. SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p.
Wu K; Li J; Qi Y; Zhang C; Zhu D; Liu D; Zhao S
Biomed Pharmacother; 2019 Aug; 116():108995. PubMed ID: 31121484
[TBL] [Abstract][Full Text] [Related]
15. miR-365a-5p suppresses gefitinib resistance in non-small-cell lung cancer through targeting PELI3.
Li F; Li H; Li S; Lv B; Shi J; Yan H; Zhang H; He Y
Pharmacogenomics; 2020 Jul; 21(11):771-783. PubMed ID: 32635799
[No Abstract] [Full Text] [Related]
16. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
17. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
Sun C; Gao W; Liu J; Cheng H; Hao J
Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16.
Wang N; Zhang T
Oncol Res; 2018 Aug; 26(7):1005-1014. PubMed ID: 29295721
[TBL] [Abstract][Full Text] [Related]
19. Hsa-miR-4271 downregulates the expression of constitutive androstane receptor and enhances in vivo the sensitivity of non-small cell lung cancer to gefitinib.
Wang C; Ding S; Sun B; Shen L; Xiao L; Han Z; Huang H
Pharmacol Res; 2020 Nov; 161():105110. PubMed ID: 32755614
[TBL] [Abstract][Full Text] [Related]
20. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
